ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Hormone Refractory Prostate Cancer (HRPCA) - Global Market Insights and Sales Trends 2024
Published Date: November 2023
|
Report Code: QYRE-Auto-28R3921
Home | Market Reports | Health| Men s Health
Global Hormone Refractory Prostate Cancer HRPCA Market Insights and Forecast to 2028
BUY CHAPTERS

Hormone Refractory Prostate Cancer (HRPCA) - Global Market Insights and Sales Trends 2024

Code: QYRE-Auto-28R3921
Report
November 2023
Pages:62
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astellas
Sanofi
Dendreon Corporation, Bayer AG
Johnson & Johnson

Hormone Refractory Prostate Cancer (HRPCA) - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Hormone Refractory Prostate Cancer (HRPCA) - Market

Hormone Refractory Prostate Cancer (HRPCA) - Market

Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal Therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
The global Hormone Refractory Prostate Cancer (HRPCA) market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hormone Refractory Prostate Cancer (HRPCA) in various end use industries. The expanding demands from the Hospitals, Ambulatory Surgical Centers, Specialty Clinics and Others, are propelling Hormone Refractory Prostate Cancer (HRPCA) market. Cytotoxic Agents, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Anti-Androgens segment is estimated at % CAGR for the next seven-year period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hormone Refractory Prostate Cancer (HRPCA), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Hormone Refractory Prostate Cancer (HRPCA) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hormone Refractory Prostate Cancer (HRPCA) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hormone Refractory Prostate Cancer (HRPCA) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hormone Refractory Prostate Cancer (HRPCA) covered in this report include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc.
The global Hormone Refractory Prostate Cancer (HRPCA) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson

Scope of Hormone Refractory Prostate Cancer (HRPCA) - Market Report

Report Metric Details
Report Name Hormone Refractory Prostate Cancer (HRPCA) - Market
CAGR 5%
Global Hormone Refractory Prostate Cancer (HRPCA) market, by region:
  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, etc.)
  • Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
  • South America (Brazil, etc.)
  • Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hormone Refractory Prostate Cancer (HRPCA) market, Segment by Type:
  • Cytotoxic Agents
  • Anti-Androgens
  • Vaccines
  • Radio-Pharmaceuticals
Global Hormone Refractory Prostate Cancer (HRPCA) market, by Application
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Others
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter Four: Detailed analysis of Hormone Refractory Prostate Cancer (HRPCA) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
  • Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
  • Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter Twelve: Research Finding/Conclusion

FAQ for this report

What are the Application segmentation covered in the Hormone Refractory Prostate Cancer (HRPCA) - Market report?

Ans: The Applications covered in the Hormone Refractory Prostate Cancer (HRPCA) - Market report are Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others

What are the Type segmentation covered in the Hormone Refractory Prostate Cancer (HRPCA) - Market report?

Ans: The Types covered in the Hormone Refractory Prostate Cancer (HRPCA) - Market report are Cytotoxic Agents, Anti-Androgens, Vaccines, Radio-Pharmaceuticals

1 Market Overview of Hormone Refractory Prostate Cancer (HRPCA)
1.1 Hormone Refractory Prostate Cancer (HRPCA) Market Overview
1.1.1 Hormone Refractory Prostate Cancer (HRPCA) Product Scope
1.1.2 Hormone Refractory Prostate Cancer (HRPCA) Market Status and Outlook
1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2018-2029)
1.4 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Region (2018-2023)
1.5 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029)
1.6.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029)
1.6.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029)
1.6.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029)
1.6.4 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029)
1.6.5 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029)
2 Hormone Refractory Prostate Cancer (HRPCA) Market by Type
2.1 Introduction
2.1.1 Cytotoxic Agents
2.1.2 Anti-Androgens
2.1.3 Vaccines
2.1.4 Radio-Pharmaceuticals
2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Type (2018-2023)
2.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Type (2018-2029)
3 Hormone Refractory Prostate Cancer (HRPCA) Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Ambulatory Surgical Centers
3.1.3 Specialty Clinics
3.1.4 Others
3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Application (2018-2023)
3.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Breakdown by Application (2018-2029)
4 Hormone Refractory Prostate Cancer (HRPCA) Competition Analysis by Players
4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hormone Refractory Prostate Cancer (HRPCA) as of 2022)
4.3 Date of Key Players Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
4.4 Global Top Players Hormone Refractory Prostate Cancer (HRPCA) Headquarters and Area Served
4.5 Key Players Hormone Refractory Prostate Cancer (HRPCA) Product Solution and Service
4.6 Competitive Status
4.6.1 Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Astellas Inc
5.1.1 Astellas Inc Profile
5.1.2 Astellas Inc Main Business
5.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Products, Services and Solutions
5.1.4 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) & (2018-2023)
5.1.5 Astellas Inc Recent Developments
5.2 Sanofi S.A
5.2.1 Sanofi S.A Profile
5.2.2 Sanofi S.A Main Business
5.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Products, Services and Solutions
5.2.4 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) & (2018-2023)
5.2.5 Sanofi S.A Recent Developments
5.3 Dendreon Corporation, Bayer AG
5.3.1 Dendreon Corporation, Bayer AG Profile
5.3.2 Dendreon Corporation, Bayer AG Main Business
5.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Products, Services and Solutions
5.3.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) & (2018-2023)
5.3.5 Johnson & Johnson Recent Developments
5.4 Johnson & Johnson
5.4.1 Johnson & Johnson Profile
5.4.2 Johnson & Johnson Main Business
5.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Products, Services and Solutions
5.4.4 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) & (2018-2023)
5.4.5 Johnson & Johnson Recent Developments
6 North America
6.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hormone Refractory Prostate Cancer (HRPCA) Market Dynamics
11.1 Hormone Refractory Prostate Cancer (HRPCA) Industry Trends
11.2 Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
11.3 Hormone Refractory Prostate Cancer (HRPCA) Market Challenges
11.4 Hormone Refractory Prostate Cancer (HRPCA) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
FEATURED COMPANIES
Astellas
Sanofi
Dendreon Corporation, Bayer AG
Johnson & Johnson
List of Tables
    Table 1. Global Market Hormone Refractory Prostate Cancer (HRPCA) Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
    Table 2. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2018-2023) & (US$ Million)
    Table 3. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Region (2018-2023)
    Table 4. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 5. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size Share by Region (2024-2029)
    Table 6. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
    Table 7. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2018-2023) & (US$ Million)
    Table 8. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2018-2023)
    Table 9. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 10. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2024-2029)
    Table 11. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2018-2023) & (US$ Million)
    Table 12. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2024-2029) & (US$ Million)
    Table 13. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2018-2023) & (US$ Million)
    Table 14. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2024-2029) & (US$ Million)
    Table 15. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2018-2023) & (US$ Million)
    Table 16. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2024-2029) & (US$ Million)
    Table 17. Latin America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2018-2023) & (US$ Million)
    Table 18. Latin America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2024-2029) & (US$ Million)
    Table 19. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2018-2023) & (US$ Million)
    Table 20. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type (2024-2029) & (US$ Million)
    Table 21. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
    Table 22. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2018-2023) & (US$ Million)
    Table 23. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2018-2023)
    Table 24. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 25. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2024-2029)
    Table 26. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2018-2023) & (US$ Million)
    Table 27. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2024-2029) & (US$ Million)
    Table 28. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2018-2023) & (US$ Million)
    Table 29. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2024-2029) & (US$ Million)
    Table 30. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2018-2023) & (US$ Million)
    Table 31. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2024-2029) & (US$ Million)
    Table 32. Latin America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2018-2023) & (US$ Million)
    Table 33. Latin America Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2024-2029) & (US$ Million)
    Table 34. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2018-2023) & (US$ Million)
    Table 35. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application (2024-2029) & (US$ Million)
    Table 36. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$ Million) by Players (2018-2023)
    Table 37. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Players (2018-2023)
    Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hormone Refractory Prostate Cancer (HRPCA) as of 2022)
    Table 39. Date of Key Players Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
    Table 40. Global Hormone Refractory Prostate Cancer (HRPCA) Key Players Headquarters and Area Served
    Table 41. Hormone Refractory Prostate Cancer (HRPCA) Product Solution and Service
    Table 42. Global Hormone Refractory Prostate Cancer (HRPCA) Players Market Concentration Ratio (CR5 and HHI)
    Table 43. Mergers & Acquisitions, Expansion Plans
    Table 44. Astellas Inc Basic Information List
    Table 45. Astellas Inc Description and Business Overview
    Table 46. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Products, Services and Solutions
    Table 47. Revenue (US$ Million) in Hormone Refractory Prostate Cancer (HRPCA) Business of Astellas Inc (2018-2023)
    Table 48. Astellas Inc Recent Developments
    Table 49. Sanofi S.A Basic Information List
    Table 50. Sanofi S.A Description and Business Overview
    Table 51. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Products, Services and Solutions
    Table 52. Revenue (US$ Million) in Hormone Refractory Prostate Cancer (HRPCA) Business of Sanofi S.A (2018-2023)
    Table 53. Sanofi S.A Recent Developments
    Table 54. Dendreon Corporation, Bayer AG Basic Information List
    Table 55. Dendreon Corporation, Bayer AG Description and Business Overview
    Table 56. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Products, Services and Solutions
    Table 57. Revenue (US$ Million) in Hormone Refractory Prostate Cancer (HRPCA) Business of Dendreon Corporation, Bayer AG (2018-2023)
    Table 58. Dendreon Corporation, Bayer AG Recent Developments
    Table 59. Johnson & Johnson Basic Information List
    Table 60. Johnson & Johnson Description and Business Overview
    Table 61. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Products, Services and Solutions
    Table 62. Revenue (US$ Million) in Hormone Refractory Prostate Cancer (HRPCA) Business of Johnson & Johnson (2018-2023)
    Table 63. Johnson & Johnson Recent Developments
    Table 64. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2018-2023) & (US$ Million)
    Table 65. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2024-2029) & (US$ Million)
    Table 66. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2018-2023) & (US$ Million)
    Table 67. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2024-2029) & (US$ Million)
    Table 68. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 69. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2018-2023) & (US$ Million)
    Table 70. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2024-2029) & (US$ Million)
    Table 71. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2018-2023)
    Table 72. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2024-2029)
    Table 73. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 74. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2018-2023) & (US$ Million)
    Table 75. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2024-2029) & (US$ Million)
    Table 76. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 77. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2018-2023) & (US$ Million)
    Table 78. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2024-2029) & (US$ Million)
    Table 79. Hormone Refractory Prostate Cancer (HRPCA) Market Trends
    Table 80. Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
    Table 81. Hormone Refractory Prostate Cancer (HRPCA) Market Challenges
    Table 82. Hormone Refractory Prostate Cancer (HRPCA) Market Restraints
    Table 83. Research Programs/Design for This Report
    Table 84. Key Data Information from Secondary Sources
    Table 85. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Year-over-Year 2018-2029 & (US$ Million)
    Figure 2. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (US$ Million), 2018 VS 2022 VS 2029
    Figure 3. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Regions: 2022 VS 2029
    Figure 4. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size Share by Region (2024-2029)
    Figure 5. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 6. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 7. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 8. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 9. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 10. Product Picture of Cytotoxic Agents
    Figure 11. Global Cytotoxic Agents Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 12. Product Picture of Anti-Androgens
    Figure 13. Global Anti-Androgens Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 14. Product Picture of Vaccines
    Figure 15. Global Vaccines Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 16. Product Picture of Radio-Pharmaceuticals
    Figure 17. Global Radio-Pharmaceuticals Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 18. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Type: 2022 & 2029
    Figure 19. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2018-2029)
    Figure 20. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2018-2029)
    Figure 21. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2018-2029)
    Figure 22. Latin America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2018-2029)
    Figure 23. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2018-2029)
    Figure 24. Hospitals Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 25. Ambulatory Surgical Centers Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 26. Specialty Clinics Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 27. Others Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 28. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Application: 2022 & 2029
    Figure 29. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2018-2029)
    Figure 30. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2018-2029)
    Figure 31. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2018-2029)
    Figure 32. Latin America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2018-2029)
    Figure 33. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application (2018-2029)
    Figure 34. Hormone Refractory Prostate Cancer (HRPCA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 35. Global Top 5 and Top 10 Players Hormone Refractory Prostate Cancer (HRPCA) Market Share in 2022
    Figure 36. North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2018-2029)
    Figure 37. U.S. Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 38. Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 39. Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 40. France Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 41. U.K. Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 42. Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 43. Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 44. Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 45. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2018-2029)
    Figure 46. China Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 47. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 48. South Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 49. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 50. India Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 51. Australia Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 52. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2018-2029)
    Figure 53. Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 54. Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 55. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Country (2018-2029)
    Figure 56. Turkey Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 57. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 58. UAE Hormone Refractory Prostate Cancer (HRPCA) Market Size (2018-2029) & (US$ Million)
    Figure 59. Bottom-up and Top-down Approaches for This Report
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3350

This license allows only one user to access the PDF.
Electronic (PDF)

$5025

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$6700

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions